Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

Authors:
Tianxia Li Bo Ning Lingbo Kong Bingling Dai Xiaofei He Joseph M Thomas Akira Sawa Christopher A Ross Wanli W Smith

Cells 2021 Feb 23;10(2). Epub 2021 Feb 23.

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Mutations in gene cause autosomal-dominant Parkinson's disease (PD) and contribute to sporadic PD. Common genetic variation in LRRK2 modifies susceptibility to immunological disorders including Crohn's disease and leprosy. Previous studies have reported that LRRK2 is expressed in B lymphocytes and macrophages, suggesting a role for LRRK2 in immunological functions. In this study, we characterized the LRRK2 protein expression and phosphorylation using human lymphoblasts. Lipopolysaccharide (LPS), a proinflammatory agent, induced the increase of LRRK2 expression and kinase activities in human lymphoblasts in a time-dependent manner. Moreover, LPS activated the Toll-like receptor (TLR) signaling pathway, increased TRAF6/LRRK2 interaction, and elevated the phosphorylation levels of MAPK (JNK1/2, p38, and ERK1/2) and IkBα. Treatment with LRRK2 inhibitor 68 reduced LPS-induced TRAF6/LRRK2 interaction and MAPK and IkBα phosphorylation, thereby reducing TNF-α secretion. These results indicate that LRRK2 is actively involved in proinflammatory responses in human lymphoblasts, and inhibition of GTP binding by 68 results in an anti-inflammation effect against proinflammatory stimuli. These findings not only provide novel insights into the mechanisms of LRRK2-linked immune and inflammatory responses in B-cell-like lymphoblasts, but also suggest that 68 may also have potential therapeutic value for LRRK2-linked immunological disorders.

Download full-text PDF

 Source
http://dx.doi.org/10.3390/cells10020480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926966PMC
February 2021

Publication Analysis

Top Keywords

human lymphoblasts
16
gtp binding
8
traf6/lrrk2 interaction
8
immunological disorders
8
lrrk2
8
lymphoblasts
5
pathway increased
4
increased traf6/lrrk2
4
lrrk2 protein
4
signaling pathway
4
tlr signaling
4
toll-like receptor
4
receptor tlr
4
interaction elevated
4
characterized lrrk2
4
jnk1/2 p38
4
p38 erk1/2
4
erk1/2 ikbα
4
mapk jnk1/2
4
levels mapk
4

Keyword Occurance

Similar Publications

The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.

Authors:
Luana Naia Philip Ly Sandra I Mota Carla Lopes Carina Maranga Patrícia Coelho Noga Gershoni-Emek Maria Ankarcrona Michal Geva Michael R Hayden A Cristina Rego

Neurotherapeutics 2021 Apr 1. Epub 2021 Apr 1.

CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

Pridopidine is a selective Sigma-1 receptor (S1R) agonist in clinical development for Huntington disease (HD) and amyotrophic lateral sclerosis. S1R is a chaperone protein localized in mitochondria-associated endoplasmic reticulum (ER) membranes, a signaling platform that regulates Ca signaling, reactive oxygen species (ROS) and mitochondrial fission. Here, we investigate the protective effects of pridopidine on various mitochondrial functions in human and mouse HD models. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Pathologically Relevant Mouse Models for Epstein-Barr Virus-Associated B Cell Lymphoma.

Authors:
Shiyu Huang Tomoharu Yasuda

Front Immunol 2021 24;12:639844. Epub 2021 Feb 24.

Department of Immunology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

The Epstein-Barr virus (EBV) is endemic in humans and can efficiently transform infected B cells under some circumstances. If an EBV carrier experiences immune suppression, EBV B cells can turn into lymphoblasts and exhibit growth expansion that may cause lymphoproliferative diseases which often develop into lymphoma. Our immune system conducts surveillance for EBV B cells in order to block spontaneous tumor formation. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

Authors:
Tianxia Li Bo Ning Lingbo Kong Bingling Dai Xiaofei He Joseph M Thomas Akira Sawa Christopher A Ross Wanli W Smith

Cells 2021 Feb 23;10(2). Epub 2021 Feb 23.

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Mutations in gene cause autosomal-dominant Parkinson's disease (PD) and contribute to sporadic PD. Common genetic variation in LRRK2 modifies susceptibility to immunological disorders including Crohn's disease and leprosy. Previous studies have reported that LRRK2 is expressed in B lymphocytes and macrophages, suggesting a role for LRRK2 in immunological functions. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

SFPQ regulates the accumulation of RNA foci and dipeptide repeat proteins from the expanded repeat mutation in .

Authors:
Mirjana Malnar Boris Rogelj

J Cell Sci 2021 Feb 19;134(4). Epub 2021 Feb 19.

Department of Biotechnology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia

The expanded GGGGCC repeat mutation in the gene is the most common genetic cause of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The expansion is transcribed to sense and antisense RNA, which form RNA foci and bind cellular proteins. This mechanism of action is considered cytotoxic. Read More

View Article and Full-Text PDF
February 2021
Similar Publications